A Phase 2/3 interventional study of Epinephrine 4mg nasal powder spray and Adrenalin 0.5mg Injectable Product in Anaphylaxis Food, sponsored by Nasus Pharma. Enrolling by invitation at 1 site in Israel. Open to participants aged 18 Years to 40 Years. Per ClinicalTrials.gov, last updated 2025-07-01.
Sponsored by Nasus Pharma · Phase 2/3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies testing epinephrine in Anaphylaxis — 3 open to participants now, 3 under way, 1 of them phase 3. Epinephrine · Anaphylaxis.
Among the 11 studies testing epinephrine in Anaphylaxis, this one is the 3rd largest by planned enrollment, is one of 3 that started in 2025, is the only one in phase 2/3, and was the 9th registered.
101 studies on the registry are indexed under Anaphylaxis; 21 are open to participants now.
Browse Anaphylaxis studies →3 of the 11 studies testing epinephrine in Anaphylaxis are open now, in 2 countries. Recruiting first, the newest first:
Dr. George Luciuk · Sites in Canada
Ages 12+
Nasus Pharma · Sites in Canada
Ages 18–55 · Healthy volunteers
By country, each count listing its studies:
Epinephrine: first FDA approval 1948 (XYLOCAINE W/ EPINEPHRINE), first EMA approval 2024. What it is approved for, and how studies give it, is on its page →
Of the 17 Anaphylaxis studies recruiting now, 10 (59%) set no upper age limit and 6 (35%) stop at 75 or younger; 11 take children under 18; 4 take healthy volunteers.
This study: 18 Years to 40 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 3 · Phase 3 1 · Phase 4 2
First in 2010; this study’s year is marked. 3 started in 2025.
This study's planned enrollment of 30 is below the median of 40 across 51 interventional studies indexed under Anaphylaxis.
Median enrollment 23 across the 11 interventional studies. Of the 8 that completed or were terminated, 2 (25%) have results posted.
This tab as a report to print or save as PDF → With an account.
7 of 11 have an industry lead sponsor. The 6 most frequent:
Nasus Pharma is the lead sponsor of 7 studies on the registry; 3 are open to participants now.
Nasus Pharma has 4 studies filed under Anaphylaxis — fewer than ten, so there is no comparison to draw.
1 of the studies testing epinephrine in Anaphylaxis that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07038746Dr. George LuciukEffects of Inhaled Epinephrine on Systemic Allergic Reactions During Allergy Testing, Immunotherapy or Oral Challenges | 2026-12 |
Add it to your calendar (.ics) → With an account.
Among the 11 studies testing epinephrine in Anaphylaxis, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Study Objective To evaluate the efficacy of FMXIN002, a powder-based intranasal epinephrine spray, for treating anaphylaxis.
Study Design
Study Procedures
Treatment Criteria: If a Grade II or III anaphylactic reaction occurs, the participant will receive either:
A). Intranasal spray of epinephrine FMXIN002 4mg + placebo saline injection B). Intranasal spray of placebo + intramuscular epinephrine injection (Adrenalin 0.5mg)
One administration will always be epinephrine; the other, placebo.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Epinephrine powder nasal spray together with a placebo IM injection
Combination Product: Epinephrine 4mg nasal powder spray
Epinephrine IM injection together with a placebo nasal spray
Combination Product: Adrenalin 0.5mg Injectable Product
Epinephrine nasal powder spray in a unidose nasal applicator device. Will be administered together with a placebo saline IM injection
Also known as: FMXIN002
Epinephrine 0.5mg for IM injection. Will be administered together with a placebo nasal powder spray.
Skin system anaphylaxis symptoms
Severity grading system for acute allergic reactions. Skin system, severity score 0 (=no reaction) to 5(= severe reaction), based on the Delphi study, 2021
Time frame: 0-90 minutes after drug administration
Mucosal system anaphylaxis symptoms
Severity grading system for acute allergic reactions, mucosal system, severity score 0 (=no reaction) to 5(= severe reaction), based on the Delphi study, 2021
Time frame: 0-90 minutes after drug administration
Gastrointestinal system anaphylaxis symptoms
Severity grading system for acute allergic reactions, gastrointestinal system, severity score 0 (=no reaction) to 5(= severe reaction), based on the Delphi study, 2021.
Time frame: 0-90 minutes after drug administration
Respiratory system anaphylaxis symptoms
Severity grading system for acute allergic reactions, respiratory system, severity score 0 (=no reaction) to 5(= severe reaction), based on the Delphi study, 2021.
Time frame: 0-90 minutes after drug administration
Total anaphylaxis severity score
Severity grading system for acute allergic reactions, Combined systems, anaphylaxis score 0 (=no reaction) to 5(= severe reaction), based on the Delphi study, 2021.
Time frame: 0-90 minutes after drug administration
Vital signs: Blood pressure
Systolic and diastolic blood pressure by a blood pressure cuff
Time frame: 0-90 minutes after drug administration
Vital signs: pulse rate
heart rate by pulse rate measurement
Time frame: 0-90 minutes after drug administration
Vital signs: oxygen saturation
% oxygen saturation measurement using oxygen monitor
Time frame: 0-90 minutes after drug administration
Need for a second epinephrine dose
Number of patients needed a second dose, by Adrenalin IM injection
Time frame: 0-90 minutes after drug administration
Adverse events
Any treatment-related adverse events
Time frame: 0-90 minutes after drug administration
Plan to share: No
No publications or documents are linked to this record.
Started Jun 2025 (actual). Primary completion is estimated for Jun 2026, 12 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Epinephrine
Nasus Pharma